Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
R-209 by Douglas Pharmaceuticals for Inflammatory Bowel Disease: Likelihood of Approval
R-209 is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData,...